Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriMix-DC vaccine plus ipilimumab in unresectable stage III/IV melanoma
2010-023058-35Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TriMix-DC and ipilimumab in melanoma, sponsored by UZ Brussel. Primary endpoint: Disease control rate (irRC). Started Dec 2010; status: completed.
02
Drugs
TriMix-DCipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-023058-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023058-35.